Atomic AI develops next-generation RNA-centric medicines using machine learning and structural biology. Their ATOM-1 foundation model provides highly precise predictions of three-dimensional RNA structure, enabling access to previously unreachable therapeutic targets. The proprietary R&D platform integrates deep learning models with purpose-built wet-lab assays to accelerate drug discovery.
Funding
$42M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery methods for RNA-targeted therapeutics are slow and inefficient, hindering the development of treatments for diseases involving RNA dysfunction. Identifying small molecules and RNA-based medicines that can selectively bind to and modulate RNA targets remains a significant challenge.
Solution
Atomic AI is developing an AI-driven platform that integrates deep learning and structural biology to accelerate the discovery and design of RNA-targeted therapeutics. The platform utilizes deep learning foundation models to identify novel RNA targets, predict RNA structure, and design small molecules and RNA-based medicines with atomic precision. By combining computational power with biological insights, Atomic AI aims to create precise and effective treatments for a wide range of diseases.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, and research institutions focused on developing RNA-targeted therapeutics.
Features
- Deep learning models for RNA structure prediction and target identification
- AI-driven design of RNA-targeted small molecules and RNA-based therapeutics
- Integration of structural biology data for enhanced accuracy
- Proprietary platform for rapid screening and optimization of drug candidates